The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Authors
Keywords
-
Journal
Journal of Crohns & Colitis
Volume 12, Issue 1, Pages 105-119
Publisher
Oxford University Press (OUP)
Online
2017-08-22
DOI
10.1093/ecco-jcc/jjx117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- OP034 Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
- (2017) W.J. Sandborn et al. Journal of Crohns & Colitis
- OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease
- (2017) W.J. Sandborn et al. Journal of Crohns & Colitis
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
- (2016) Clara Yzet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
- (2016) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- (2016) A Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells
- (2016) Shuntaro Tsukamoto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
- (2016) Maria Rosario et al. CLINICAL DRUG INVESTIGATION
- Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
- (2016) Shomron Ben-Horin et al. Clinical Gastroenterology and Hepatology
- Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
- (2016) Antonio Delgado et al. CURRENT MEDICINAL CHEMISTRY
- Sphingosine-1-phosphate receptor: a novel therapeutic target in ulcerative colitis
- (2016) Roberta Izzo et al. Expert Review of Clinical Immunology
- Sa1934 Pharmacokinetics and Exposure-Response Relationships of Ustekinumab during IV Induction and SC Maintenance Treatment of Patients with Crohn's Disease with Ustekinumab: Results from the UNITI-1, UNITI-2, and IM-UNITI Studies
- (2016) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- 767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials
- (2016) William Sandborn et al. GASTROENTEROLOGY
- Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis
- (2016) Franck Carbonnel et al. GASTROENTEROLOGY
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial
- (2016) Takayuki Matsumoto et al. Journal of Crohns & Colitis
- ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
- (2016) Silvio Danese et al. Journal of Crohns & Colitis
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
- (2016) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells and endothelium and modulated during inflammatory bowel disease
- (2016) T Karuppuchamy et al. Mucosal Immunology
- Biosimilars in IBD: from theory to practice
- (2016) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
- (2016) Sumit Kunwar et al. RHEUMATOLOGY INTERNATIONAL
- The emerging role of FTY720 (Fingolimod) in cancer treatment
- (2016) Christopher White et al. Oncotarget
- Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease
- (2015) Robert Hirten et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Integrins and adhesion molecules as targets to treat inflammatory bowel disease
- (2015) Ivana Bravatà et al. CURRENT OPINION IN PHARMACOLOGY
- 830 Initial Evaluation of MEDI2070 (Specific Anti-IL-23 Antibody) in Patients With Active Crohn's Disease Who Have Failed Anti-TNF Antibody Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 2A Induction Study
- (2015) Bruce E. Sands et al. GASTROENTEROLOGY
- Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
- (2015) Naoki Yoshimura et al. GASTROENTEROLOGY
- Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice
- (2015) Barrett G. Levesque et al. GASTROENTEROLOGY
- Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice
- (2015) Niels Vande Casteele et al. JOURNAL OF CLINICAL PHARMACOLOGY
- OP022. Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study
- (2015) Journal of Crohns & Colitis
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
- (2015) Reena Khanna et al. LANCET
- Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
- (2015) Giovanni Monteleone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Long-Term Outcome of Enterocutaneous Fistula in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Cohort Study from the GETAID
- (2014) Aurelien Amiot et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Not all monoclonals are created equal – Lessons from failed drug trials in Crohn's disease
- (2014) Arthur Kaser BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies
- (2014) M. Rosario et al. Journal of Crohns & Colitis
- Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
- (2014) Christel J. Menet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Antidrug antibodies in psoriasis: a systematic review
- (2013) L. Hsu et al. BRITISH JOURNAL OF DERMATOLOGY
- TGF-Beta Signaling Manipulation as Potential Therapy for IBD
- (2013) Irene Marafini et al. CURRENT DRUG TARGETS
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
- (2013) Brian G. Feagan et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease
- (2013) Federico Argüelles-Arias et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Anti-TNF and Fistulising Perianal Crohns Disease: Use in Clinical Practice
- (2010) Leonidas Bourikas et al. CURRENT DRUG TARGETS
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease
- (2009) Kai Wang et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
- (2009) William J. Sandborn et al. GASTROENTEROLOGY
- Intracellular signal pathways: Potential for therapies
- (2009) Melissa Mavers et al. Current Rheumatology Reports
- Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study
- (2008) Brian G. Feagan et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now